Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Divarasib - Genentech

Next Previous
Drug Profile

Divarasib - Genentech

Alternative Names: GDC-6036; RG 6330; RO-7435846

Latest Information Update: 28 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; Roche
  • Class Aminopyridines; Antineoplastics; Chlorinated hydrocarbons; Fluorine compounds; Ketones; Piperazines; Pyrrolidines; Quinazolines; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I Breast cancer; Solid tumours

Most Recent Events

  • 09 Jan 2026 Hoffmann-La Roche plans a phase III KRASCENDO 3 trial for Non small cell lung cancer (Second-line therapy or greater) in January 2026 (PO) (NCT07541170; CTIS2025-524263-21-00)
  • 27 Nov 2025 Genentech completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT06734208)
  • 05 Nov 2025 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in United Kingdom, Switzerland, South Korea, Poland, Germany, Brazil (PO) (NCT06793215) (EUCT2024-518365-10-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top